Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory...

por Ogasawara, Ken, Dodds, Michael, Mack, Timothy, Lymp, James, Dell’Aringa, Justine, Smith, Jeff
Publicado 2021

Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Ly...

por Ogasawara, Ken, Dodds, Michael, Mack, Timothy, Lymp, James, Dell’Aringa, Justine, Smith, Jeff
Publicado 2021

In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B‐Cell Lymphoma

por Ogasawara, Ken, Lymp, James, Mack, Timothy, Dell’Aringa, Justine, Huang, Chang‐pin, Smith, Jeff, Peiser, Leanne, Kostic, Ana
Publicado 2022

Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies

por Ogasawara, Ken, Newhall, Kathryn, Maxwell, Stephen E., Dell’Aringa, Justine, Komashko, Vitalina, Kilavuz, Nurgul, Delarue, Richard, Czuczman, Myron, Sternas, Lars, Rose, Shelonitda, Beach, C. L., Novick, Steven, Zhou, Simon, Palmisano, Maria, Li, Yan
Publicado 2019

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

por Casulo, Carla, Santoro, Armando, Cartron, Guillaume, Ando, Kiyoshi, Munoz, Javier, Le Gouill, Steven, Izutsu, Koji, Rule, Simon, Lugtenburg, Pieternella, Ruan, Jia, Arcaini, Luca, Casadebaig, Marie‐Laure, Fox, Brian, Kilavuz, Nurgul, Rettby, Nils, Dell'Aringa, Justine, Taningco, Lilia, Delarue, Richard, Czuczman, Myron, Witzig, Thomas
Publicado 2022